Genomic Health, Inc. (GHDX) Q2 2012 Earnings Call August 8, 2012 4:30 pm ET Executives Emily Faucette – Senior Director, Corporate Communications and Investor Relations Kimberly Popovits – Chairman of the Board, Chief Executive Officer and President Bradley Cole – Chief Operating Officer Dean Schorno – Chief Financial Officer Steven Shak – Executive Vice President of Research and Development and Chief Medical Officer Kathy Hibbs – Senior Vice President & General Counsel Joffre Baker – Chief Scientific Officer Randal Scott – Founder and Director, Genomic Health and Chief Executive Officer, InVitae Corporation Analysts Dane Leone – Macquarie Research Tycho Peterson – JPMorgan David Clair – Piper Jaffray Amanda Murphy – William Blair Dan Leonard – Leerink Swann Kevin DeGeeter – Ladenburg Thalmann & Co. Scott Gleason – Stephens Inc. Laura McGuigan – B. Riley Nicholas Jansen – Raymond James PresentationOperator
Good afternoon. My name is Chuck, and I will be your conference operator today. At this time I would like to welcome everyone to Genomic Health’s Second Quarter 2012 Financial Results Conference Call. All participants are in a listen-only mode. Later we will conduct a question-and-answer session, and instructions will follow at that time. (Operator instructions) I would now like to turn the call over to Emily Faucette, Senior Director of Corporate Communications and Investor Relations. You may begin your conference. Emily Faucette Thank you. Good afternoon everyone and welcome to Genomic Health conference call to review our second-quarter 2012 financial results. Before we begin, I would like to remind you that various remarks that we make on this call that are not historical, including those about our future financial and operating results, our plans and prospects, our ability to leverage our existing infrastructure, the success of our business strategy, economic benefits and value to payers of our tests, growth opportunities, future products, product enhancements and our product pipeline, demand for our tests and drivers of demand, payer coverage and progress in reimbursement and patient access, our investments in our business, clinical outcomes and timing of clinical studies, and product launches, and our expectations regarding our ability to comply with potential FDA regulation constitute forward-looking statements within the meaning of the safe harbor provision of the Private Securities Litigation Reform Act.